Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BCL2L1 overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

BCL2/BCL2L1 ratio elevation (3)

Chr t(11;14) + BCL2 : BCL2L1 ratio elevation (1)

BCL2/BCL2L1 ratio elevation (3)

Chr t(11;14) + BCL2 : BCL2L1 ratio elevation (1)

›

BCL2L1 overexpression	Diffuse Large B Cell Lymphoma	BCL2L1 overexpression	Diffuse Large B Cell Lymphoma	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3
BCL2L1 overexpression	Acute Lymphocytic Leukemia	BCL2L1 overexpression	Acute Lymphocytic Leukemia	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3
BCL2L1 overexpression	Non Small Cell Lung Cancer	BCL2L1 overexpression	Non Small Cell Lung Cancer	osimertinib + APG-1252 Sensitive: C3 – Early Trials osimertinib + APG-1252 Sensitive : C3	osimertinib + APG-1252 Sensitive: C3 – Early Trials osimertinib + APG-1252 Sensitive : C3
BCL2L1 overexpression	Multiple Myeloma	BCL2L1 overexpression	Multiple Myeloma	venetoclax Sensitive: D – Preclinical venetoclax Sensitive : D	venetoclax Sensitive: D – Preclinical venetoclax Sensitive : D
BCL2L1 overexpression	Gastric Cancer	BCL2L1 overexpression	Gastric Cancer	APG-1252 Sensitive: D – Preclinical APG-1252 Sensitive : D	APG-1252 Sensitive: D – Preclinical APG-1252 Sensitive : D
BCL2L1 overexpression	Mantle Cell Lymphoma	BCL2L1 overexpression	Mantle Cell Lymphoma	venetoclax Resistant: D – Preclinical venetoclax Resistant : D	venetoclax Resistant: D – Preclinical venetoclax Resistant : D
BCL2L1 overexpression	Acute Myelogenous Leukemia	BCL2L1 overexpression	Acute Myelogenous Leukemia	venetoclax + AZD5991 Sensitive: D – Preclinical venetoclax + AZD5991 Sensitive : D	venetoclax + AZD5991 Sensitive: D – Preclinical venetoclax + AZD5991 Sensitive : D
BCL2L1 overexpression	Pancreatic Cancer	BCL2L1 overexpression	Pancreatic Cancer	ACR-368 + ABT 263 Sensitive: D – Preclinical ACR-368 + ABT 263 Sensitive : D	ACR-368 + ABT 263 Sensitive: D – Preclinical ACR-368 + ABT 263 Sensitive : D
BCL2L1 overexpression	Mantle Cell Lymphoma	BCL2L1 overexpression	Mantle Cell Lymphoma	venetoclax + trametinib Resistant: D – Preclinical venetoclax + trametinib Resistant : D	venetoclax + trametinib Resistant: D – Preclinical venetoclax + trametinib Resistant : D
BCL2L1 overexpression	Multiple Myeloma	BCL2L1 overexpression	Multiple Myeloma	venetoclax + trametinib Resistant: D – Preclinical venetoclax + trametinib Resistant : D	venetoclax + trametinib Resistant: D – Preclinical venetoclax + trametinib Resistant : D
BCL2L1 overexpression	Chronic Lymphocytic Leukemia	BCL2L1 overexpression	Chronic Lymphocytic Leukemia	venetoclax + trametinib Resistant: D – Preclinical venetoclax + trametinib Resistant : D	venetoclax + trametinib Resistant: D – Preclinical venetoclax + trametinib Resistant : D